Key facts
- This page summarizes Daniel Wintner Goodman's Form 4 filing for Tonix Pharmaceuticals Holding Corp. (TNXP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2021, 09:07.
Daniel Wintner Goodman - 25 May 2021 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)
- Reporting relationship
- Director
- Issuer ticker
- TNXP
- Reported as of
- 25 May 2021
- Net transaction value
- +$5,600
- SEC form
- 4
- Accepted by SEC
- 26 May 2021, 09:07:43 UTC
- Prior SEC filing
- 12 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jessica Morris, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel Wintner Goodman filed Form 4 for Tonix Pharmaceuticals Holding Corp. (TNXP) on 26 May 2021.
Change
- Previous filing in this sequence was filed on 12 May 2021.
- Current net transaction value: +$5,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TNXP
transaction
Common Stock
Purchase
- Transaction value
- $5,600
- Shares
- +5,000
- Change %
- +500000%
- Price
- $1.12
- Shares after
- 5,001
- Date
- 25 May 2021
- Ownership
- Direct
* marks a reported price that did not pass the local price check.